September 26, 2006
Urodynamix Initiates US Clinical Study of NIRS Technology
For Immediate Release:
Vancouver, British Columbia - (September 26, 2006) Urodynamix Technologies Ltd. (TSX-V:URO) announced today that it has initiated the first US-based clinical study to assess the effectiveness of its near-infrared spectroscopy (“NIRS”) urodynamics device for measuring bladder function in male subjects with obstruction or lower urinary tract symptoms (“LUTS”). LUTS is caused by prostate disease and benign prostatic hyperplasia (“BPH”), a condition affecting 30 million men throughout North America.
Specifically, the study will determine whether URO-NIRS technology is as effective as conventional invasive urodynamics evaluation in male subjects who experience LUTS. Urodynamix expects to enroll 24 patients in the clinical study over the next 8 weeks. The goal of the study is to collect data using the URO-NIRS device and corroborate results obtained in a previous study conducted at the Bladder Care Centre at the University of British Columbia using an early prototype (see news release dated July 5, 2006 for details). The study will be led by principal investigator Dr. Donna Deng, MD, Assistant Professor of Urology at UCSF Medical Center in San Francisco.
“Our current method for performing urodynamic studies is invasive and uncomfortable for the patient,” said Dr. Deng. “The technology behind URO-NIRS is very exciting and could be revolutionary to the practice of urology.”
This is the first of several studies planned for the Company’s NIRS prototype leading up to pivotal clinical trials in 2007. Compared to the early prototype, the Urodynamix URO-NIRS prototype is equipped with advanced features including automatic laser attenuation control, analog and digital signal processing and an integrated data management system. URO-NIRS technology is completely non-invasive, and may allow urologists to develop more effective treatment plans for patients affected by prostate diseases and other urinary incontinences in men and women.
“We are pleased that our first study using the Urodynamix URO-NIRS device is underway and excited about the opportunity to work with Dr. Deng,” said Barry Allen, President and CEO of Urodynamix. “We believe that data collected in this study will provide additional confirmation that NIRS offers a better diagnostic option to physicians treating BPH patients who suffer from urinary incontinence. We hope to improve the quality of care for these patients by providing a comfortable, non-invasive alternative to conventional catheter-based urodynamics testing.”
About Urodynamix Technologies Ltd.
Urodynamix Technologies Ltd. is the world leader in non-invasive measurement of bladder function and urological conditions. Urodynamix is focused on the development and commercialization of breakthrough diagnostic technology for bladder conditions specifically urinary incontinence (UI). Urodynamix is currently developing a family of non-invasive diagnostic and monitoring technologies for the over 200 Million UI sufferers worldwide.
On behalf of the Board,
“Barry Allen”
President & CEO
Urodynamix Technologies Ltd.
Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein.Al though the Company believes that the expectations reflected in such forward-looking statements are reasonable; it can give no assurance that such expectations will prove correct.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Craig Pamplin
Director, Corporate Development and Communications
Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com
|
